FIND Joins CARB-X to Support Development of Diagnostics to Combat Antimicrobial Resistance

Feb 26, 2019

NEW YORK (360Dx) – The Foundation for Innovative New Diagnostics (FIND) is joining the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) Global Accelerator Network, the organizations announced today.

The CARB-X Global Accelerator Network now includes 10 organizations that provide business, scientific, and technical expertise and services to CARB-X-funded companies to support their antibacterial research projects.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

FIND Joins CARB-X to Support Development of Diagnostics to Combat Antimicrobial Resistance

To read the full story....

Breaking News

Illumina Wins NIPT Infringement Suit Against Roche's Ariosa Diagnostics

USPTO Denies Foundation Medicine Attempt to Invalidate Guardant Health Patent

In Brief This Week: SpeeDx, Abbott

Bio-Techne Gets New York State Approval for Prostate Cancer Test

FDA Issues Draft Recommendations For Biotin Interference Testing

FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

At-Home Tests for Influenza, Strep, Others Raising Eyebrows of Some Experts

FDA Clears Roche Extraction Platform For Use With Applied BioCode GI Pathogen Panel, System

FDA Issues Draft Recommendations For Biotin Interference Testing

Fujifilm, FIND Developing Urine-Based, Point-of-Care TB Test With Higher Accuracy

Aperture Bio Developing Automated Test to Detect UTIs, Guide Antibiotic Treatment

Sponsorships